Disclosed are a thioredoxin mutant, preparation method thereof, and application thereof in production of recombinant fusion protein. The recombinant fusion protein produced by the expression of the thioredoxin mutant of the present invention has good solubility and stability in high-temperature environments and is not easily denatured.

An allergen inactivation method includes an inactivation step of inactivating an allergen present in a reaction system by reduction via a reduced redox protein, and a reduction process of reducing an oxidized redox protein produced by oxidation of the reduced redox protein in the inactivating to the reduced redox protein by donating an electron from an electrode connected to an external power supply outside the reaction system to the oxidized redox protein.

The present invention relates to a modified TXNIP protein, a method for preparing the modified TXNIP protein, a polynucleotide encoding the modified protein, an expression vector including the polynucleotide, a transformant introduced with the expression vector, a method for crystallizing a modified TRX-TXNIP complex using the modified TXNIP protein, and a method for screening a substance regulating interaction between TRX and TXNIP, an inhibitor of TRX activity, or a substance regulating TXNIP function.

Compositions and methods for improving plant growth are provided herein. Disclosed herein are polypeptides encompassing m-type thioredoxin proteins, and polynucleotides encoding m-type thioredoxin proteins, wherein the thioredoxin protein-encoding sequence is expressed from mesophyll-preferred promoters. Also provided herein are expression constructs for expressing genes of interest whose expression may improve agronomic properties including but not limited to crop yield, biotic and abiotic stress tolerance, and early vigor, plants comprising the polynucleotides, polypeptides, and expression constructs, and methods of producing transgenic plants.

A pharmaceutically compatible antioxidant for use in the treatment or the prevention of an unwanted immune response, the corresponding pharmaceutical and vaccine compositions, and the corresponding clinical and ex-vivo applications.

Provided are extracellular vesicles (EVs) derived from a recombinant microorganism including one or more polynucleotides encoding one or more target proteins, extracellular vesicles isolated from the microorganism, and a use of the extracellular vesicles.

A fusion protein is described, comprising a first N-terminal signal peptide sequence, a second peptide sequence C-terminal to the signal peptide sequence, and a third peptide sequence C-terminal to the second peptide sequence; wherein one of the second peptide sequence and the third peptide sequence is an RdCVF-short peptide sequence and the other is a hydrophilic peptide sequence. After translation the signal peptide is cleaved, leaving a fusion protein comprising the second peptide sequence and the third peptide sequence minus the signal peptide. Also described are nucleic acids and expression vectors encoding the fusion protein, cells comprising the nucleic acid or expression vector, as well as methods of treatment and uses of the fusion protein, nucleic acid, and expression vector. The fusion protein can be produced in vitro by culturing the cells of this invention under conditions allowing for expression and secretion of the encoded fusion protein, and isolating the fusion protein from the cell culture.

A fusion protein is described, comprising a first N-terminal signal peptide sequence, a second peptide sequence C-terminal to the signal peptide sequence, and a third peptide sequence C-terminal to the second peptide sequence; wherein one of the second peptide sequence and the third peptide sequence is an RdCVF-short peptide sequence and the other is a hydrophilic peptide sequence. After translation the signal peptide is cleaved, leaving a fusion protein comprising the second peptide sequence and the third peptide sequence minus the signal peptide. Also described are nucleic acids and expression vectors encoding the fusion protein, cells comprising the nucleic acid or expression vector, as well as methods of treatment and uses of the fusion protein, nucleic acid, and expression vector. The fusion protein can be produced in vitro by culturing the cells of this invention under conditions allowing for expression and secretion of the encoded fusion protein, and isolating the fusion protein from the cell culture.

The present invention relates to a method for upregulation of thioredoxin expression in stem cells and, more particularly, to a method for upregulation of thioredoxin expression in stem cells, the method comprising a step of culturing stem cells in a hypoxic condition, the stem cells having an upregulated expression of thioredoxin by the same method, and a use of the stem cells in treatment of ischemic brain disease. When cultured in a hypoxic condition, stem cells are able to have increased expression of thioredoxin and stem cells that have an upregulated expression level of thioredoxin exhibiting an excellent therapeutic effect on ischemic brain disease can be obtained by the method. Thus, the stem cells can be usefully applied in the prevention or treatment of ischemic brain disease.

Compositions and methods for improving plant growth are provided herein. Polynucleotides encoding thioredoxin proteins, polypeptides encompassing thioredoxin proteins, and expression constructs for expressing genes of interest whose expression may improve agronomic properties including but not limited to crop yield, biotic and abiotic stress tolerance, and early vigor, plants comprising the polynucleotides, polypeptides, and expression constructs, and methods of producing transgenic plants are also provided.